Nexentis Technologies Inc. (NXTS) AI Stock Summary

Snapshot

N2OFF is a distressed micro-cap that generated zero revenue in FY 2025 while reporting a net loss of $4.0M. The company burns cash at a rate of $3.8M per year, which gives it a cash runway of roughly seven months. To maintain its stock price and listing, the management executed two reverse stock splits in the last year, a 1-for-35 split and a 1-for-7 split, which are often signs of prolonged share price pressure. While the company describes itself as an agri-tech firm, recent activity focuses on its drug discovery subsidiary MitoCareX, which has achieved early R&D milestones but produces no revenue yet.

What's Happening Right Now

• Mon 22nd Jun '26 · Partnership: Nexentis announced an AI drug discovery initiative between its subsidiary MitoCareX Bio and Boltz PBC to combine their technologies for virtual screening.
• Mon 18th May '26 · R&D Milestone: MitoCareX Bio generated an optimized hit molecule with improved pharmaceutical properties, marking its first drug discovery milestone since acquisition.
• Tue 5th May '26 · Trademark: The company received U.S. trademark registration for its MITOLINE algorithm platform used for 3D modeling of mitochondrial proteins.

Ownership

Institutions hold 2.7% and insiders hold 19.0%.

Bottom Line

This stock is primarily a liquidity risk right now. With zero revenue and only seven months of cash remaining, the company is in a precarious position that forces immediate focus on survival. The recent reverse splits confirm the stock has been under severe pressure. A reader looking at this name must be comfortable with a high risk of insolvency before evaluating the potential of the MitoCareX drug discovery platform.